A Multicenter Compassionate Use Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

Trial Profile

A Multicenter Compassionate Use Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Expanded access; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Sep 2016 Results (N=485) assessing safety and efficacy published in the Gut (2016).
    • 17 Apr 2016 Results of subanalysis of HCV-infected patients (n=147) with decompensated cirrhosis treated with a combination of daclatasvir + sofosbuvir +/- ribavirin were presented at The International Liver Congress™ 2016.
    • 26 Jan 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top